Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Conclusion As the global obesity epidemic surges toward unprecedented levels, with around 220 million people projected to be affected by 2030 in the 7MM, the pharmaceutical industry finds itself in a high-stakes innovation race that may redefine chronic disease management
Renal function: When initiating or escalating doses and in patients reporting severe adverse reactions, especially in patients with renal impairment
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
The existing conceptual uncertainty complicates trial design, data interpretation, and ultimately, clinical translation
Additional benefits, including cardiovascular risk reduction and kidney-protective effects, have further solidified their place in therapy
g was determined by two-way ANOVA followed by Bonferroni post-hoc analysis
US$ 20.71
US$ 22.20
US$ 20.21
US$ 24.68
US$ 20.17
US$ 21.12
US$ 21.93
US$ 28.43
US$ 20.14
